Your Data Migration Questions Answered: Ask the Expert Q&A Panel
This webcast will give attendees who are considering or in the process of replacing and/or transitioning EHRs the ability to ask questions of our experts. Our moderators have extensive experience in data migration efforts, having supported over 250+ projects, and migration of 40MM+ patient records and 7K+ providers. They will be available to answer questions surrounding changes in workflows, items to consider when migrating data, knowing what to migrate vs archive, etc.
Julia Snapp & Tyler Suacci
Presented July 11th, 2017
Q & A
Q: Do you use automated validation tools or sampling techniques in your validation step?
A: In regards to automated validation tools, we do have some validation tools and those are dependent on the EHR that we are migrating into. For example, for data migrations to EHRs where we are directly inserting data into the database (such as Allscripts TouchWorks), we have processes in our GalenETL platform that compare the legacy data to the data that was migrated into TouchWorks, identify any differences, and report them out to the project team. We also have some tools that, regardless of the EHR, we can use to validate or even automate the mappings. The validation and mapping tools are stronger when standard code sets (SNOMED, RxNorm, LOINC, etc.) exist, but we can also validate or auto-map based on name alone.
In regards to sampling techniques for validation, each of our data migrations will use a hybrid approach in selecting patients for validation. Usually for small scale validation, which is our first round of validation, 25 patients are selected due to something unique on their chart. It may be that during the data evaluation process we determined that they had the largest medication list, or largest note. Those 25 patients are not usually a random selection but are selected due to something specific that we are looking to validate. Then for our large and full scale rounds of validation, we use statistics to determine our testing population. Those patients are selected at random. Generally, we test around 300 patients per database. Based on our experience we run into very few new issues when we hit full scale validation which is our last round of validation.